Mark Keating is a co-founder of and serves as a scientific advisor to City Therapeutics. Since 2016 Dr. Keating has been consulting for biotechnology companies and investors.

Dr. Keating was appointed Chief Scientific Officer of Yarrow Biotechnology in 2021. Before that he served as Vice President and Distinguished Fellow at Alnylam Pharmaceuticals, where he focused on CNS and ocular RNAi targets, starting in 2018. In 2005, Dr. Keating joined Novartis where he founded the Departments of Ophthalmology and Genetics, focusing on age-related macular degeneration. He then became the global leader of Cardiovascular and Metabolic Disease Research, creating an innovative pipeline aimed at heart failure, atherosclerosis, diabetes and inherited disorders. Prior to that in 2001, Dr. Keating co-founded Hydra Biosciences, a venture-backed biotechnology company in Cambridge, Massachusetts.

Dr. Keating began his independent laboratory as a faculty member in the Departments of Human Genetics, Medicine and Pediatrics (1989-2000) and the Howard Hughes Medical Institute (1994-2000) at the University of Utah. There, Keating focused on the molecular genetics and physiology of cardiovascular disease. His laboratory did pioneering work on long QT syndrome (LQTS), discovering LQT genes such as HERG and also developed the diagnostic test for Williams Syndrome. Dr. Keating moved his laboratory to the Howard Hughes Medical Institute and the Departments of Cell Biology and Pediatrics at Harvard Medical School and Children’s Hospital (2000-2005). His work at Harvard focused on developing zebrafish as a molecular genetic model for studying regeneration, particularly cardiac regeneration.

Dr. Keating graduated from Princeton with an A.B. in biology in 1976 and received his M.D. from Johns Hopkins in 1980, followed by an internship and residency in internal medicine at Johns Hopkins Hospital. Dr. Keating then completed a cardiology fellowship and a postdoctoral research fellowship at University of California, San Francisco. Dr. Keating was elected to the National Academy of Sciences in 2004 and the American Academy of Arts and Sciences in 2006.